NASDAQ:ORPH

Orphazyme A/S Competitors

$5.97
-0.55 (-8.44 %)
(As of 06/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.84
$6.34
50-Day Range
$4.82
$21.00
52-Week Range
$4.75
$77.77
Volume8.88 million shs
Average Volume4.01 million shs
Market Capitalization$208.66 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Orphazyme A/S (NASDAQ:ORPH) Vs. MRUS, COLL, AFMD, KPTI, SLN, and CRNX

Should you be buying ORPH stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Orphazyme A/S, including Merus (MRUS), Collegium Pharmaceutical (COLL), Affimed (AFMD), Karyopharm Therapeutics (KPTI), Silence Therapeutics (SLN), and Crinetics Pharmaceuticals (CRNX).

Merus (NASDAQ:MRUS) and Orphazyme A/S (NASDAQ:ORPH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Analyst Ratings

This is a summary of current recommendations for Merus and Orphazyme A/S, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merus01502.83
Orphazyme A/S21001.33

Merus presently has a consensus price target of $29.40, indicating a potential upside of 35.17%. Orphazyme A/S has a consensus price target of $16.00, indicating a potential upside of 168.01%. Given Orphazyme A/S's higher possible upside, analysts plainly believe Orphazyme A/S is more favorable than Merus.

Profitability

This table compares Merus and Orphazyme A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merus-248.38%-57.90%-28.43%
Orphazyme A/SN/AN/AN/A

Valuation and Earnings

This table compares Merus and Orphazyme A/S's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merus$29.94 million27.86$-85,510,000.00($2.60)-8.37
Orphazyme A/SN/AN/A$-97,010,000.00($3.42)-1.75

Merus has higher revenue and earnings than Orphazyme A/S. Merus is trading at a lower price-to-earnings ratio than Orphazyme A/S, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

69.7% of Merus shares are owned by institutional investors. Comparatively, 0.8% of Orphazyme A/S shares are owned by institutional investors. 2.9% of Merus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Merus beats Orphazyme A/S on 7 of the 12 factors compared between the two stocks.

Collegium Pharmaceutical (NASDAQ:COLL) and Orphazyme A/S (NASDAQ:ORPH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Analyst Ratings

This is a summary of current recommendations for Collegium Pharmaceutical and Orphazyme A/S, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Collegium Pharmaceutical10202.33
Orphazyme A/S21001.33

Collegium Pharmaceutical presently has a consensus price target of $25.00, indicating a potential upside of 8.60%. Orphazyme A/S has a consensus price target of $16.00, indicating a potential upside of 168.01%. Given Orphazyme A/S's higher possible upside, analysts plainly believe Orphazyme A/S is more favorable than Collegium Pharmaceutical.

Profitability

This table compares Collegium Pharmaceutical and Orphazyme A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Collegium Pharmaceutical13.06%24.52%6.50%
Orphazyme A/SN/AN/AN/A

Valuation and Earnings

This table compares Collegium Pharmaceutical and Orphazyme A/S's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Collegium Pharmaceutical$310.02 million2.62$26.75 million$0.7630.29
Orphazyme A/SN/AN/A$-97,010,000.00($3.42)-1.75

Collegium Pharmaceutical has higher revenue and earnings than Orphazyme A/S. Orphazyme A/S is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

0.8% of Orphazyme A/S shares are owned by institutional investors. 5.2% of Collegium Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Collegium Pharmaceutical beats Orphazyme A/S on 10 of the 12 factors compared between the two stocks.

Affimed (NASDAQ:AFMD) and Orphazyme A/S (NASDAQ:ORPH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Profitability

This table compares Affimed and Orphazyme A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Affimed-144.10%-87.56%-34.72%
Orphazyme A/SN/AN/AN/A

Insider and Institutional Ownership

79.7% of Affimed shares are owned by institutional investors. Comparatively, 0.8% of Orphazyme A/S shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Affimed and Orphazyme A/S's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Affimed$32.39 million25.00$-47,250,000.00($0.57)-14.46
Orphazyme A/SN/AN/A$-97,010,000.00($3.42)-1.75

Affimed has higher revenue and earnings than Orphazyme A/S. Affimed is trading at a lower price-to-earnings ratio than Orphazyme A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for Affimed and Orphazyme A/S, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Affimed00503.00
Orphazyme A/S21001.33

Affimed presently has a consensus price target of $13.80, indicating a potential upside of 67.48%. Orphazyme A/S has a consensus price target of $16.00, indicating a potential upside of 168.01%. Given Orphazyme A/S's higher possible upside, analysts plainly believe Orphazyme A/S is more favorable than Affimed.

Summary

Affimed beats Orphazyme A/S on 6 of the 11 factors compared between the two stocks.

Karyopharm Therapeutics (NASDAQ:KPTI) and Orphazyme A/S (NASDAQ:ORPH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Profitability

This table compares Karyopharm Therapeutics and Orphazyme A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Karyopharm Therapeutics-177.34%-357.73%-61.51%
Orphazyme A/SN/AN/AN/A

Institutional and Insider Ownership

80.1% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 0.8% of Orphazyme A/S shares are owned by institutional investors. 10.2% of Karyopharm Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Karyopharm Therapeutics and Orphazyme A/S's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Karyopharm Therapeutics$108.08 million7.25$-196,270,000.00($2.72)-3.83
Orphazyme A/SN/AN/A$-97,010,000.00($3.42)-1.75

Orphazyme A/S has lower revenue, but higher earnings than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than Orphazyme A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Karyopharm Therapeutics and Orphazyme A/S, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Karyopharm Therapeutics01702.88
Orphazyme A/S21001.33

Karyopharm Therapeutics currently has a consensus target price of $27.75, indicating a potential upside of 166.06%. Orphazyme A/S has a consensus target price of $16.00, indicating a potential upside of 168.01%. Given Orphazyme A/S's higher possible upside, analysts clearly believe Orphazyme A/S is more favorable than Karyopharm Therapeutics.

Silence Therapeutics (NASDAQ:SLN) and Orphazyme A/S (NASDAQ:ORPH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Profitability

This table compares Silence Therapeutics and Orphazyme A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Silence TherapeuticsN/AN/AN/A
Orphazyme A/SN/AN/AN/A

Institutional and Insider Ownership

8.6% of Silence Therapeutics shares are owned by institutional investors. Comparatively, 0.8% of Orphazyme A/S shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Silence Therapeutics and Orphazyme A/S's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silence Therapeutics$5.48 million140.92$-41,790,000.00($0.40)-64.80
Orphazyme A/SN/AN/A$-97,010,000.00($3.42)-1.75

Silence Therapeutics has higher revenue and earnings than Orphazyme A/S. Silence Therapeutics is trading at a lower price-to-earnings ratio than Orphazyme A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Silence Therapeutics and Orphazyme A/S, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Silence Therapeutics00203.00
Orphazyme A/S21001.33

Orphazyme A/S has a consensus target price of $16.00, indicating a potential upside of 168.01%. Given Orphazyme A/S's higher possible upside, analysts clearly believe Orphazyme A/S is more favorable than Silence Therapeutics.

Summary

Silence Therapeutics beats Orphazyme A/S on 6 of the 8 factors compared between the two stocks.

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Orphazyme A/S (NASDAQ:ORPH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Profitability

This table compares Crinetics Pharmaceuticals and Orphazyme A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Crinetics PharmaceuticalsN/A-44.81%-41.52%
Orphazyme A/SN/AN/AN/A

Institutional and Insider Ownership

81.6% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.8% of Orphazyme A/S shares are owned by institutional investors. 7.4% of Crinetics Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Crinetics Pharmaceuticals and Orphazyme A/S's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Crinetics Pharmaceuticals$70,000.0010,864.38$-73,810,000.00($2.42)-8.36
Orphazyme A/SN/AN/A$-97,010,000.00($3.42)-1.75

Crinetics Pharmaceuticals has higher revenue and earnings than Orphazyme A/S. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Orphazyme A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Crinetics Pharmaceuticals and Orphazyme A/S, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Crinetics Pharmaceuticals00503.00
Orphazyme A/S21001.33

Crinetics Pharmaceuticals currently has a consensus target price of $36.25, indicating a potential upside of 79.19%. Orphazyme A/S has a consensus target price of $16.00, indicating a potential upside of 168.01%. Given Orphazyme A/S's higher possible upside, analysts clearly believe Orphazyme A/S is more favorable than Crinetics Pharmaceuticals.

Summary

Crinetics Pharmaceuticals beats Orphazyme A/S on 7 of the 11 factors compared between the two stocks.

Ad All Marijuana Stocks
Seattle Cannabis Blockbuster Set to Double Sales in Next 2 Years!
Thanks to a recent reorganization, acquisitions, and strategic partnerships, one Seattle cannabis blockbuster is poised for a massive expansion in the coming 24 months. With plans to double its annual sales in the next two years, this company’s shares could potentially skyrocket in value.

Orphazyme A/S Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Merus logo
MRUS
Merus
1.5$21.75-0.5%$834.11 million$29.94 million-8.37
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.6$23.02-1.6%$811.41 million$310.02 million19.84
Affimed logo
AFMD
Affimed
1.7$8.24-2.9%$809.89 million$32.39 million-14.21
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.9$10.43-1.3%$783.22 million$108.08 million-3.83
Silence Therapeutics logo
SLN
Silence Therapeutics
1.0$25.92-0.0%$772.26 million$5.48 million-64.80Gap Up
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$20.23-0.7%$760.51 million$70,000.00-8.29
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.8$19.63-4.5%$758.99 millionN/A-2.50News Coverage
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$18.27-1.4%$748.47 million$32.17 million-18.09
Verastem logo
VSTM
Verastem
1.5$4.28-13.3%$735.81 million$88.52 million-15.85
Evolus logo
EOLS
Evolus
1.1$13.58-1.6%$734.95 million$56.54 million-3.32
Sesen Bio logo
SESN
Sesen Bio
1.3$4.14-0.7%$717.41 million$11.24 million-4.65
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$4.21-1.2%$716.39 million$108.62 million-60.13
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$29.69-1.3%$714.88 million$10.39 million-10.80
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.6$21.50-4.7%$707.48 million$19.54 million-17.62
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.3$28.33-1.2%$707.43 million$90,000.00-12.21
Ardelyx logo
ARDX
Ardelyx
1.7$7.15-0.4%$705.77 million$7.57 million-6.27
Pharming Group logo
PHAR
Pharming Group
0.6$10.95-4.9%$702.21 million$212.10 million18.88News Coverage
Gap Down
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$13.89-3.2%$695.22 million$135.08 million60.39
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$20.58-1.3%$682.47 million$312.69 million-3.06
Veru logo
VERU
Veru
1.3$8.51-0.4%$678.11 million$42.59 million-283.57Insider Selling
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.6$18.44-2.5%$676.67 millionN/A-6.98
Chimerix logo
CMRX
Chimerix
1.7$7.84-4.6%$675.89 million$5.37 million-4.51
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.5$4.68-0.9%$675.74 million$24 million-36.00
AnaptysBio logo
ANAB
AnaptysBio
1.5$24.68-3.1%$675.47 million$75 million-22.04Analyst Report
Gap Up
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.6$18.41-2.6%$674.41 million$1.72 million-7.55Unusual Options Activity
News Coverage
Albireo Pharma logo
ALBO
Albireo Pharma
1.7$34.74-1.8%$666.83 million$8.31 million-5.01
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
2.2$23.42-3.6%$660.26 million$227.55 million-3.81News Coverage
Kadmon logo
KDMN
Kadmon
1.8$3.82-4.7%$656.94 million$8.29 million-5.79
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$11.31-5.4%$651.81 millionN/A-10.47
Clene logo
CLNN
Clene
1.9$10.86-4.1%$646.97 million$210,000.00-8.83
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.5$14.48-7.2%$646.04 million$830,000.00-3.56
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.6$26.20-0.7%$639.88 million$12.69 million-12.36
Summit Therapeutics logo
SMMT
Summit Therapeutics
1.1$6.56-0.5%$637.93 million$20.17 million-7.45
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.93-6.4%$634.78 million$109.33 million-3.30News Coverage
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.28-2.3%$628.54 millionN/A-2.39
Clovis Oncology logo
CLVS
Clovis Oncology
1.2$5.88-1.4%$614.84 million$164.52 million-1.59
Adagene logo
ADAG
Adagene
1.3$14.01-0.9%$609.69 million$700,000.00-5.29News Coverage
Applied Therapeutics logo
APLT
Applied Therapeutics
1.4$23.09-2.9%$602.21 millionN/A-4.95
Altimmune logo
ALT
Altimmune
1.6$15.56-0.5%$597.46 million$8.19 million-7.67
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
2.3$5.77-0.5%$596.41 million$119.07 million8.49
Annovis Bio logo
ANVS
Annovis Bio
1.5$84.25-14.1%$585.29 millionN/A0.00Gap Down
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$15.99-0.1%$581.05 million$230,000.00-0.72
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.5$3.62-0.6%$579.62 million$295.31 million-1.32
AC Immune logo
ACIU
AC Immune
1.3$7.87-3.0%$571.78 million$16.46 million-7.42Analyst Upgrade
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.4$2.63-0.0%$566.83 million$150,000.00-6.57News Coverage
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.4$42.52-2.6%$557.40 million$187.80 million40.11
VACC
Vaccitech
2.2$16.00-8.1%$549.25 millionN/A0.00Gap Up
IVERIC bio logo
ISEE
IVERIC bio
1.6$5.98-1.0%$539.22 millionN/A-5.20Analyst Revision
Inventiva logo
IVA
Inventiva
0.0$13.95-0.4%$538.70 million$430,000.00-12.34
Provention Bio logo
PRVB
Provention Bio
1.7$8.37-2.5%$530.45 millionN/A-3.97
This page was last updated on 6/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.